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Abstract
Background: Tropheryma whipplei, the agent of Whipple’s disease, causes localised infections in the absence of
histological digestive involvement. Our objective is to describe T. whipplei encephalitis.
Methods: We first diagnosed a patient presenting dementia and obesity whose brain biopsy and cerebrospinal
fluid specimens contained T. whipplei DNA and who responded dramatically to antibiotic treatment. We
subsequently tested cerebrospinal fluid specimens and brain biopsies sent to our laboratory using T. whipplei PCR
assays. PAS-staining and T. whipplei immunohistochemistry were also performed on brain biopsies. Analysis was
conducted for 824 cerebrospinal fluid specimens and 16 brain biopsies.
Results: We diagnosed seven patients with T. whipplei encephalitis who demonstrated no digestive involvement.
Detailed clinical histories were available for 5 of them. Regular PCR that targeted a monocopy sequence,
PAS-staining and immunohistochemistry were negative; however, several highly sensitive and specific PCR assays
targeting a repeated sequence were positive. Cognitive impairments and ataxia were the most common
neurologic manifestations. Weight gain was paradoxically observed for 2 patients. The patients’ responses to the
antibiotic treatment were dramatic and included weight loss in the obese patients.
Conclusions: We describe a new clinical condition in patients with dementia and obesity or ataxia linked to
T. whipplei that may be cured with antibiotics.
Background
Whipple’s disease is a paradigm of the evolution of
infectious disease knowledge [1]. The disease was first
described in 1907 by Whipple [2], who based it on ana-
tomopathological lesions identified in a patient at
autopsy. For many years, it was considered to be a
metabolic disorder; however, in 1952, a bacterial origin
became suspected when antibiotic treatment proved
effective [3]. The first molecular identification of the
bacterium associated with Whipple’sd i s e a s e( Tropher-
yma whipplei), as well as the first culture, created a new
field [4,5]. T. whipplei h a sb e e ni d e n t i f i e di nt h e
saliva and stool specimens of healthy people [1]. The
well-known and classic form of Whipple’sd i s e a s e ,
which is characterised by periodic acid-Schiff (PAS)-
stained bacilli in infected small-bowel macrophages,
represents only one rare clinical form of the infection
that can be caused by T. whipplei. Indeed, the bacterium
has also been involved in subacute or chronic infections
without gut lesions, such as endocarditis, encephalitis,
uveitis, adenopathy and pulmonary and osteoarticular
infections [1,6-9]. The diagnosis and management are
different for each of these infections [1,9,10]. Finally,
acute T. whipplei infections, such as pneumonia [11,12],
gastroenteritis [13] and transit bacteraemia [14], have
recently been reported.
Neurologic forms are often the most serious manifes-
tations of T. whipplei infection, particularly with respect
to relapse treatment failure [15]. It has been noticed
that relapses of classic Whipple’s disease can be
* Correspondence: didier.raoult@gmail.com
1Unité des rickettsies, URMITE CNRS-IRD UMR 6236, IFR 48, Faculté de
médecine, Université de la Méditerranée, Marseille, France
Full list of author information is available at the end of the article
Fenollar et al. BMC Infectious Diseases 2011, 11:171
http://www.biomedcentral.com/1471-2334/11/171
© 2011 Fenollar et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.exclusively cerebral, without any peripheral manifestations
[1]. We recently diagnosed infection with T. whipplei in
a patient who presented with progressive dementia
and recent-onset obesity and responded dramatically to
antibiotic treatment. This observation encouraged us to
document additional cases of T. whipplei infections using
brain biopsies and cerebrospinal fluid specimens.
Methods
Patients
Patients from the study
From January 2001 to June 2009, 824 cerebrospinal fluid
specimens and 16 brain biopsies from patients without a
previous diagnosis of Whipple’s disease were analysed
using PCR for T. whipplei in our laboratory in Marseille,
France, which is a reference centre for T. whipplei diag-
nosis in our country. All samples were collected as part
of routine clinical management, and they were sent to
our laboratory for the detection of all microorganisms
potentially responsible for encephalitis. Our diagnostic
criteria for T. whipplei encephalitis required at least two
positive PCR assays targeting 2 different sequences on 2
different cerebrospinal fluid specimens, performed as
previously reported, or positive PCR assays on brain
biopsies [16,17] and negative results PAS staining of
gastric and small-bowel specimens, plus an absence of
meningitis, myelitis, and other organ involvement. Our
study is in compliance with the Helsinki declaration.
The local ethics committee from IFR 48 (Marseille,
France) approved this study. Written informed consent
was obtained from the patient for the use of information
in this case report and any accompanying images.
Patients from the literature
A MEDLINE (National Library of Medicine, Bethesda,
MD) search of the literature from 1966 to April 2010
was performed. The following terms were used, both
alone and combined: Tropheryma whipplei, Tropheryma
whippelii, Whipple’s disease, brain, cerebral, encephalitis
and cerebrospinal fluid. References prior to 1966 were
searched by cross referencing. Our initial analysis indi-
cated considerable confusion in the literature regarding
t h es p e c i f i cd i a g n o s i so fT. whipplei encephalitis. We
then applied rigorous criteria to classify the diagnosis as
certain, possible or excluded. The diagnosis was consid-
ered certain only for patients with positive T. whipplei
PCR, which allows the specific identification of the bac-
terium, and those with a negative PAS staining from
gastric and small-bowel biopsies. Patients for whom
digestive biopsies were not available were excluded from
further analysis. Patients for whom the diagnosis was
based solely on PAS staining of brain biopsies were also
excluded; among 12 brain biopsies sent to our labora-
tory to confirm T. whipplei encephalitis (Table 1), all
showed a nonspecific inflammatory process of the brain
with numerous PAS-positive macrophages in the white
matter, but specific immunohistochemistry yielded nega-
tive results. Patients who exhibited structures suggestive
of bacterium under electron microscopy, along with
positive PAS staining on brain biopsies, were classified
as possible T. whipplei infection cases, as were patients
with a diagnosis based exclusively on oculomasticatory
myorhythmia. This rigorous strategy resulted in fewer
patients with localised neurologic manifestations than
have previously been reported [1].
Methods
PCR assays, serologic studies and isolation procedures
PCR assays were performed as previously reported
[16-20]. Two hundred μl cerebrospinal fluid specimens
were submitted for DNA extraction using the QIAamp
DNA MiniKit (Qiagen, Hilden, German) according to
the manufacturer’s recommendations. PCR mixes were
prepared using a Fast-Start DNA Master SYBR Green
kit (Roche, Mannheim, Germany) following the manu-
facturer’s instructions. Quantitative PCR (qPCR) was
performed in a LightCycler thermocycler (Roche bio-
chemicals, Mannheim, Germany). For each assay, posi-
tive and negative controls were used. At intervals of 5
samples, negative controls (water, PCR mix and human
samples) were evaluated. A tenfold dilution of a stan-
dard suspension of 10
6 T. whipplei strain Marseille-
Twist was used as a positive control and for quantifica-
tion, as previously reported [21]. The quality of DNA
extraction from samples was estimated by PCR targeting
a housekeeping gene coding b-actin. If a first PCR assay
was positive, the result was systematically confirmed by
as e c o n dP C Ra s s a yu s i n gas e c o n ds e to fp r i m e rp a i r s .
In the event of discrepancies between the two PCR
assays or incorrect controls, samples were submitted to
new DNA extraction and/or new qPCR assays.
T h eP C Rp r i m e r st h a tw eu s e dh a v ee v o l v e dw i t h
improved knowledge about T. whipplei. Between January
2001 and February 2004, all samples were tested using
our regular qPCR, targeting a 489-bp fragment of the
16S-23S rRNA gene intergenic spacer using the primers
tws3f (5’-CCGGTGACTTAACCTTTTTGGAGA) and
tws4r (5’-TCCCGAGGCTTATCGCAGATTG), as pre-
viously reported [17]. If this assay was positive, a 650-bp
fragment of the rpoB gene using the primers TWRPOB.
F( 5 ’-TTTTTCCGGCGTGCGCTCAA) and TWRPOB.R
(5’-TTTCTCCGAGGTTGCGGTGC) was performed
[17]. For all of the assays, when an amplified product
was detected, T. whipplei was systematically confirmed
by sequencing, as previously reported [19]. Since Octo-
ber 2003, the availability of the T. whipplei genome has
offered the option of using repeated sequences of
T. whipplei for highly sensitive and specific PCR assays
[16]. Subsequently, a PCR targeting repeated sequences
Fenollar et al. BMC Infectious Diseases 2011, 11:171
http://www.biomedcentral.com/1471-2334/11/171
Page 2 of 9of T. whipplei was developed that, when an amplified
product was detected, confirmed the identification of T.
whipplei by sequencing (between October 2003 and
March 2004) or by using specific oligonucleotide
Taqman* probes (since April 2004). From October 2003
to March 2004, T. whipplei qPCR targeting a 164-bp
sequence of the bacterium incorporated the primer pairs
53.3F (5-AGAGAGATGGGGTGCAGGAC) and 53.3R
(5’-AGCCTTTGCCAGACAGACAC) into the reaction
mix. If this assay was positive, the result was confirmed
by a second assay using a second set of primer pairs,
342F (5’-AGATGATGGATCTGCTTTCTTATCTG) and
492R (5’-AACCCTGTCCTGCACCCC), which targeted
a different DNA sequence. Since April 2004, the
reaction mix has included T. whipplei qPCR targeting a
155-bp sequence of the bacterium and incorporating the
primer pair TW27F (5’-TGTTTTGTACTGCTTGTAA-
CAGGATCT) and TW182R (5’-TCCTGCTCTATC
CCTCCTATCATC) and a Taqman* probe (27F-182R,
6-FAM-AGAGATACATTTGTGTTAGTTGTTACA-
TAMRA). If this assay was positive, the result was con-
firmed by a second assay using a second set of primer
pairs TW13F (5’-TGAGTGATGGTAGTCTGAGAGA
TATGT) and TW163R (5’-TCCATAACAAAGACA
ACAACCAATC) and a Taqman* probe (13F-163R,
6-FAM-AGAAGAAGATGTTACGGGTTG-TAMRA)
targeting a different 150-bp sequence [20-22]. Finally, all
the cerebrospinal fluid specimens prior to October 2003
were retrospectively tested using PCR targeting repeated
sequences, and the specimens sampled between October
2003 and February 2004 were tested using both regular
and repeat PCR.
Serologic studies were performed as previously
reported [23]. Cerebrospinal fluid specimens were culti-
vated using both cell-culture and cell-free culture media,
as previously described [24,25].
Brain magnetic resonance imaging and spectroscopy
protocols
Brain magnetic resonance examinations were performed
on a 1.5 T Magnetom Vision Plus system (Siemens,
Erlangen, Germany). The imaging protocol included one
axial FLAIR sequence (TR = 8000 ms, TI = 180 ms,
TE = 110 ms) and one axial T1-weighted sequence (TR
= 644, ms TE = 15 ms) performed before and after con-
trast agent administration (0.2 ml/kg of Gadolinium-
D T P A ,G u e r b e t ,P a r i s ,F r a n c e ) .M a g n e t i s a t i o nt r a n s f e r
imaging was performed using two axial proton-density
weighted FLASH sequences (TR = 500 ms, TE = 4.7 ms,
21 slices, thickness = 5 mm, flip angle = 30°, without
Table 1 Summary of 14 brain biopsies from patients with encephalitis analysed in our laboratory using PAS staining,
immunohistochemistry with polyclonal rabbit antibodies specifically directed against T. whipplei and specific PCR
Brain biopsies
Patients Sex/Age Country of origin PAS staining T. whipplei immunohistochemistry T. whipplei PCR
False-positive PAS staining associated with negative immunohistochemistry
Excluded diagnosis of T. whipplei encephalitis
*1 F/67 Ireland Positive Negative Negative
*2 M/25 Canada Positive Negative Negative
*3 M/42 France Positive Negative Negative
*4 M/37 Belgium Positive Negative Negative
*5 NA/NA Japan Positive Negative Negative
*6 M/34 France Positive Negative Negative
*7 M/64 France Positive Negative Negative
*8 M/66 France Positive Negative Negative
Diagnosis of T. whipplei encephalitis not available due to lack of PCR
2
*9 M/73 Japan Positive Negative NA
1
*10 M/14 USA Positive Negative NA
1
*11 NA/NA South-Africa Positive Negative NA
1
*12 M/NA Canada Positive Negative NA
1
False-negative PAS staining and immunohistochemistry
*
2Patient 1 in this study M/39 France Negative Negative Positive
*
2Patient 5 in this study F/33 France Negative Negative Positive
NA: Not available
*: All samples from these patients were analysed in our facilities.
1: PCR assays were not available for these patients because no fresh specimens were sampled and the quality of the DNA extracted from the paraffin-embedded
specimens was poor, not allowing a conclusive diagnosis.
2: Patients were seen and followed by one of the authors (DR) in consultation.
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FOV = 240 mm, matrix size = 256 × 256). Diffusion-
weighted imaging was performed using a single-shot EPI
sequence (b = 0, 500, 1000 s/mm
2) applied in the x, y
and z directions (19 slices, thickness = 5 mm, matrix
size = 128 × 128, FOV = 256 × 256 mm
2). Apparent dif-
fusion coefficient (ADC) maps were reconstructed using
this sequence. Single voxel proton magnetic resonance
spectroscopy (SVS) included STEAM acquisition at an
echo time of 20 ms. TR was 1500 ms. One voxel was
centred on the medulla oblongata lesion, while the
reference voxel was located on a contiguous area (the
p o n s )t h a ta p p e a r e dn o r m a lo na l lM Rs e q u e n c e s .T h e
voxel volume was adapted to the size of the lesion. Sev-
eral normal brain metabolites are detected using the
STEAM 20 ms sequence: N-acetylaspartate (NAA) is an
amino acid that is present almost exclusively in neurons;
reduced levels may correspond to neuronal death or
injury. Myoinositol (MI) is a sugar that is only present
in glia. It reduces when these cells experience specific
damage and increases in cases of glial activation or pro-
liferation (in glial tumours or reactive gliosis) [26].
Other molecules are detected under pathological condi-
tions. Lactate and lipids or macromolecules may be
detected when there is a local ischemia that eventually
leads to necrosis (as with ischemic stroke and some
tumours). Lactate may also be detected in relation to a
macrophage infiltration. High lactate and lipid levels are
also detected in cases of abscess. Other molecules such
as succinate, acetate, alanine and other amino acids can
be detected using in vivo magnetic resonance spectro-
scopy in cases of brain abscess, but only when the infec-
tious lesion is cystic. Creatine/phosphocreatine (tCr) is a
ubiquitous metabolite involved in energy storage. It is a
marker of overall cellular density. Choline (Cho) is
mostly involved in cell membrane metabolism, and it is
thus a membrane turnover marker. It increases when-
ever there is cellular proliferation (as with brain
tumours), inflammation or membrane catabolism (as
with multiple sclerosis).
Statistical analysis
Data were analysed using EpiInfo software, Version 3.4.1
(Centers for Disease Control and Prevention, Atlanta,
GA, USA). P < 0.05 was considered statistically
significant.
Results
Index patient
A 39-year-old male (Patient 1) was hospitalised for cog-
nitive impairment and choreiform movements. His med-
ical history included a nearly 3-week-long period of
unexplained gastroenteritis 4 years earlier. Over a 3-year
period, the patient developed hepatitis and obesity (a
25-kilogram weight gain) associated with hypercholester-
olemia, hypertriglyceridemia and Type II diabetes. Hor-
monal evaluation showed peripheral hypoandrogenia
with elevated levels of follicle-stimulating hormone.
Brain magnetic resonance imaging (MRI) did not show
any abnormalities. One year prior to hospitalisation, he
developed dementia, dysarthria, and apathy, followed by
involuntary and almost permanent choreiform move-
ments of the left hemibody and abnormal buccofacial
movements. No blood cell count abnormalities or
C-reactive protein increases were observed. An increase
in hepatic transaminases was identified. A lumbar punc-
ture showed a high protein level (4 g/l) with a normal
glucose level. Examinations with brain computer tomo-
graphy (CT) and brain MRI and spectroscopy were
abnormal (Figure 1 and additional file 1, Figure S1). The
MRI disclosed multiple unusual lesions corresponding
to multiple brain lesions located in the medulla oblon-
gata, hypothalamus, internal side of the right temporal
lobe, fornix, lenticular nuclei and head of the caudate
nuclei. These lesions showed high signal intensity on
FLAIR images and low signal intensity on MT images,
and they were slightly enhanced on T1-weighted images
after gadolinium administration. Spectroscopy was char-
acterised by a decrease in the NAA and MI peaks (con-
sistent with neuronal and glial injury) and an increase in
lipids and macromolecules, whereas lactate and other
amino acids suggestive of an abscess were not detected.
Finally, the absence of an increase in the choline-crea-
tine ratio ruled out a demyelinating lesion or neoplasm.
A brain biopsy was taken from the right striatum; it
revealed astrocytic gliosis and vascular proliferation. No
granulomas were observed. PAS staining and T. whipplei
immunohistochemistry were negative. Regular PCR tar-
geting the intertransgenic spacer (ITS) was negative for
this brain biopsy; however, repeat PCR was positive for
both the biopsy specimen and cerebrospinal fluids. One
month after beginning specific treatment (doxycycline
200 mg, hydroxychloroquine 200 mg 3 times and tri-
methoprim-sulfamethoxazole 320 + 1,600 mg 3 times
each per day), significant improvements were observed;
however, cerebrospinal fluid showed persistent high pro-
tein levels, and repeat-PCR was still positive. After 2
months, the clinical examination was normal and, sur-
prisingly, the patient had lost 17 kg. One year after the
start of the treatment, the patient’s obesity had comple-
tely regressed, his hepatic tests were normal and he pre-
sented no evidence of diabetes; furthermore, brain MRI
revealed that the majority of the lesions had disap-
peared. After 18 months of treatment, brain MRI and
spectroscopy results were normal. The repeat PCR for
cerebrospinal fluids was negative. The treatment was
stopped. Fourteen months later, he experienced a clini-
cal relapse, with weight gain (10 kilograms), the
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headache, difficulty concentrating and increased hepatic
transaminases. Brain MRI and spectrometry showed
signs of relapse, but T. whipplei repeat PCR for CSF was
negative. A treatment based on doxycycline, hydroxy-
chloroquine and sulfadiazine (1,500 mg four times per
day) was started. All clinical abnormalities resolved,
including obesity, similar to the patient’s response to the
first treatment. After 17 months of treatment, the
patient’s brain MRI was normal and spectroscopy was
clearly improved. After 52 months, the treatment was
stopped. Seventeen months after the completion of
treatment, the patient showed no sequelae and felt well.
Other patients
The characteristics of 4 other patients with T. whipplei
encephalitis (Patients 2, 3 and 4), seen by one of the
authors (DR) in consultation, and 15 patients from the
literature (8 with confirmed T. whipplei encephalitis
and 7 with a possible diagnosis) are summarised in an
additional file 2, Table S1 [27-43]. Seventy-four
patients with Whipple’s disease with neurologic mani-
festations and sufficient clinical information were also
identified from the literature review [15,27,44-54].
Comparisons among the different groups are sum-
marised in Tables 2 and 3.
T. whipplei encephalitis has two consistent findings:
progressive cognitive impairment and the eventual
onset of obesity or ataxia. For our 5 patients, the only
diagnostic finding was a positive PCR of for cerebrosp-
inal fluid and brain biopsies. This disease arises from
the isolated involvement of T. whipplei localised to the
central nervous system, which responded to antibiotic
treatments. Among our patients and those in the lit-
erature, all 3 who did not receive antibiotics (because
T. whipplei infection was diagnoseda f t e rp o s t - m o r t e m
examination) died, compared with only 3 deaths
among those who received antibiotics. This difference
was statistically significant (p = 0.01). No specific brain
MRI abnormalities were observed. Six out of 18
patients had a normal brain MRI.
PCR assays, isolation procedure and serologic studies
Among the 824 cerebrospinal fluid specimens, 7 (0.85%)
tested positive for T. whipplei DNA with PCR; 2 out of
16 brain biopsies were PCR positive, including a sample
from one patient for whom cerebrospinal fluid was
negative. Negative and positive controls were correct,
including the amplification of the gene coding b-actin.
All of our attempts to cultivate T. whipplei from the
cerebrospinal fluid specimens of our 6 patients with
T. whipplei encephalitis and positive PCR samples were
Figure 1 Figure 1a and 1b. Magnetic resonance examinations of Patient 1. MR examinations were performed on a 1.5 T Magnetom Vision
Plus system (Siemens, Erlangen, Germany). The imaging protocol included one axial and coronal T2-weighted sequence and one axial T1-
weighted sequence, performed before and after contrast agent administration not at diagnosis but before treatment, after 18 months of
treatment, at relapse, and after 17 months of a new treatment. A multimodal MRI of Patient 1 at the time of the diagnosis disclosed multiple
brain lesions located in the medulla oblongata, the hypothalamus, the internal side of the right temporal lobe, the bilateral fornix, the lenticular
nuclei and the head of caudate nuclei. These nonspecific, but unusual, lesions have a high signal intensity on FLAIR images and low signal
intensity on MT images. They are slightly enhanced on T1-weighted images after gadolinium administration. Complete normalisation of the
FLAIR abnormalities after 18 months of treatment were observed. A new lesion appeared in the left medulla oblongata during the relapse; it was
enhanced after gadolinium injection. FLAIR abnormalities reappeared during the relapse, and lenticulocaudate gadolinium enhancement was
also observed. A complete disappearance of the lesions after 17 months of treatment and the complete disappearance of gadolinium
enhancement were also observed, in accordance with clinical improvement.
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manifestations and patients with T. whipplei chronic encephalitis
Feature Patients with
Whipple’s
disease
Patients with Whipple’s disease
and neurological manifestations
Patients with certain T.
whipplei encephalitis
Patients with possible
T. whipplei encephalitis
Patients with
certain
or possible T.
whipplei
encephalitis
No./total no. (%)
Male sex 770/886 (87) 57/74 (77) 8/13 (61.5) 4/7 (57) 12/20 (60)
Age NA 50 ± 13 50 ± 13 52 ± 12 51 ± 12
Arthralgia
or arthritis
244/335 (73) 49/74 (66) 1/11 (9) 3/7 (43) 4/18 (22)
Chronic
diarrhoea
272/335 (81) 30/74 (40.5) 0/12 0/6 0/18
Weight
loss
223/240 (93) 35/57 (47) 1/11 (9) 0/6 1/17 (6)
NA: Not available
Table 3 Clinical features* of 74 patients with Whipple’s disease (i.e., patients with histological digestive involvement
characterised by positive PAS staining) with neurologic manifestations and those with certain (13) and possible (7)
T. whipplei chronic encephalitis without digestive lesions
Neurologic
manifestations
Whipple’s disease with neurologic
manifestations
Certain T. whipplei
encephalitis
Possible T. whipplei
encephalitis
Certain and
possible
T. whipplei
encephalitis
Number of patients 74 13 7 20
Cognitive impairment 53 (72%) 9 (69%) 7 (100%) 16 (80%)
Ataxia 12 (16%) 9 (69%; p <1 0
-3) 4 (57%; p = 0.02) 13 (65%; p <1 0
-3)
Supranuclear
ophthalmoplegia
29 (39%) 5 (38%) 4 (57%) 9 (45%)
Hypothalamic
manifestations
24 (32%) 4 (31%) 2 (29%) 6 (30%)
Dysarthria 9 (12%) 4 (31%) 3 (43%) 7 (35%; p = 0.03)
Cerebellar forms 4 (5.5%) 3 (23%; p = 0.06) 3 (43%; p = 0.03) 6 (26%;
p = 0.005)
Myorhythmia 10 (13.5%) 4 (31%) 3 (43%) 7 (35%;
p = 0.045)
Oculomasticatory
myorhythmia
7 (5.5%) 2 (17%) 2 (29%) 4 (20%)
Upper motor neuron
disorder
11 (15%) 4 (31%) 3 (43%) 7 (35%)
Decreasing level of
consciousness
25 (35%) 2 (15%) 6 (75%; p = 0.01) 8 (40%)
Myoclonus 29 (39%) 3 (23%) 1 (14%) 4 (20%)
Depression 11 (15%) 3 (23%) 1 (14%) 3 (15%)
Personality changes 22 (30%) 2 (15%) 2 (29%) 4 (20%)
Headache 10 (13.5%) 1 (8%) 2 (29%) 3 (15%)
Apathy 15 (20%) 1 (8%) 1 (14%) 2 (10%)
Muscle weakness 14 (19%) 2 (15%) 2 (29%) 4 (20%)
Seizures 13 (18%) 3 (23%) 1 (14%) 4 (20%)
Nystagmus 11 (15%) 3 (23%) 1 (14%) 4 (20%)
Extrapyramidal movement
disorder
8 (11%) 2 (17%) 2 (29%) 4 (20%)
Significant p values are noted in bold.
* Neurological signs were defined as follows: “Decreasing level of consciousness” included somnolence, lethargy, and coma. “Cognitive impairment” included
abnormalities of orientation, memory, or reasoning. “Hypothalamic manifestations” included polydipsia, hyperphagia, sexual impotence, changes in the sleep-
wake cycle and insomnia, but not isolated somnolence. Oculomasticatory myorhythmia was defined as pendular vergence oscillations of the eyes that were
synchronous with masticatory myorhythmia. Both were classified as myorhythmia. “Myoclonus”, which is nonrhythmic, was distinguished from myorhythmia.
“Cerebellar forms” were considered when a patient presented dysarthria and ataxia.
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T. whipplei from the cerebrospinal fluid specimens of
patients with classic Whipple’s disease with associated
neurologic manifestations (6/8), asymptomatic neurolo-
gic involvement (2/4), or neurologic relapse (1/3) (pub-
lished and unpublished data) [1]. This difference was
statistically significant (p < 0.017). We hypothesised that
this difference might be linked to a lower amount of
bacteria in the cerebrospinal fluid specimens of patients
with T. whipplei encephalitis. Serum sample serologic
tests were available from 5 patients with T. whipplei
encephalitis. Of these, 2 showed no reaction and
3 showed low-level but specific responses to the degly-
cosylated proteins of T. whipplei, as has been observed
in patients with classic Whipple’s disease [23].
Discussion
We describe a clinical phenomenon of patients with
T. whipplei who present with isolated brain involve-
ment and respond dramatically to antibiotic treatment.
Their condition was poor and worsening at the time of
the diagnosis. As in the review of the literature, the
antibiotics address the progressive cognitive impair-
ment. In our index patient, antibiotic therapy not only
improved his clinical status but also caused a reversal
of obesity, both at the time of the initial diagnosis and
upon relapse. These observations are reminiscent of
those described in 1952 after the first successful use of
an antibiotic (chloramphenicol) to treat Whipple’sd i s -
ease, which suggested that the disease had a bacterial
origin [3].
The amount of T. whipplei DNA in the cerebrospinal
fluid specimens of the patients described in our series
was low, as demonstrated by our quantitative PCR
assays; however, we are confident that these results are
accurate, because we performed 2 PCR tests on 2 differ-
ent samples to confirm the diagnosis. Our attempts to
isolate a strain from the cerebrospinal fluid specimens
failed, although we were able to isolate strains from
other cerebrospinal fluids from patients with classic
Whipple’s disease with a good percentage of success
(60%). Even in the 2 brain biopsies from our patients,
only very low copies of T. whipplei DNA were detected.
Moreover, these 2 brain biopsies were PAS negative and
T. whipplei immunohistochemistry negative. It is also
important to note that these data are different from
those of patients in the literature with positive PAS
staining of brain biopsies. Indeed, there is a link
between the clinical picture of our patients and T. whip-
plei, but we were unable to identify histological findings
compatible with described T. whipplei-associated dis-
eases. However, it has also recently been reported that
T. whipplei DNA is highly frequent in the skin biopsies
of patients with classic Whipple’s disease, whereas PAS
staining is significantly less sensitive in the same group
[55]. Furthermore, these bacteria are alive, as a positive
culture from a skin specimen has been obtained. Over-
all, these data show that PAS staining, which was long
considered the gold standard for diagnosing T. whipplei
infection, is frequently negative, despite the presence of
T. whipplei infection.
Overall, only 4 (18%) out of 18 patients reviewed here
reported a history of arthralgia, despite its description as
a cardinal symptom of classic Whipple’s disease (73%)
[1]. Our study patients reported no chronic diarrhoea,
whereas it is observed in 81% of patients with classical
Whipple’s disease and 40.5% of patients with a neurolo-
gic presentation of Whipple’s disease [1]. It is interesting
t on o t et h a t3o fo u r5p a t i e n t sr e p o r t e dah i s t o r yo f
unexplained acute diarrhoea prior to the onset of neuro-
logic symptoms, which may correspond to primary
infection with T. whipplei, as described previously in
young children [13]. Weight loss was observed for none
of our patients and only one from the literature versus
93% of patients with classic Whipple’sd i s e a s ea n d4 7 %
of patients with a neurologic presentation of Whipple’s
disease [1]. Even more interesting, 2 of our 5 patients
developed obesity during the primary illness or during
the relapse. Several viruses have been reported to contri-
bute to weight gain in animals [56]. In humans, one
adenovirus has been also identified as a possible contri-
butor to weight gain [56]. The most likely mechanisms
are a central effect on appetite and energy expenditure
associated with hypothalamic infiltration by the patho-
gen. This clinical picture may be a particular form
caused by T. whipplei. It appears that this clinical entity
resembles a localised cerebral relapse of classic Whip-
ple’s disease when bacterial multiplication is relatively
controlled. Another interesting observation is the defi-
cient humoural responses against T. whipplei in patients
with T. whipplei encephalitis, as have been described in
patients with Whipple’s disease compared with asympto-
matic carriers [23].
This clinical entity seems rare, as only 0.85% of cere-
brospinal fluid specimens of patients with unexplained
dementia or encephalitis tested in our laboratory were
positive. However, our technique may lack sensitivity in
some cases, as the repeat PCR assays were unable to
detect T. whipplei when brain MRI-spectroscopy showed
lesions compatible with reactive disease at the time of
clinical relapse. Furthermore, the lack of information
about antibiotic treatment status prior to cerebrospinal
fluid sampling for most of the patients must also lead us
to regard this prevalence cautiously, as antibiotic use
might explain some negative PCR results. As seen in
our patients, PAS staining of brain biopsy specimens
with T. whipplei also lacks sensitivity. Furthermore, this
tests lacks specificity, as perivascular aggregates of
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setting can be seen in other macrophage-rich cerebral
disorders, such as demyelinating diseases, cerebral
infarction, and a host of infectious diseases [57]. The
results of PAS-staining of brain biopsy specimens can
neither confirm nor exclude the diagnosis of T. whipplei
encephalitis. The development of cognitive impairments
associated with ataxia or obesity should point the clini-
cian to a diagnosis of T. whipplei encephalitis.
PCR testing of cerebrospinal fluid specimens for T.
whipplei in neurological patients is clinically reasonable,
as the disease is fatal without specific treatment. As is
the case for all diagnoses performed using PCR, caution
is necessary, and a rigorous strategy should be applied
when performing and interpreting the analyses due to
the risk of false-positive results [58]. A carefully checked
positive PCR in cerebrospinal fluid specimens is suffi-
cient for diagnosis. It is important to remember the
patient for whom a Whipple’s disease diagnosis was
ruled out by negative PAS staining, despite positive
PCR, and then finally confirmed using both techniques
at the patient’s autopsy [59].
Another question concerns the management of this
presentation. Advances in knowledge, with in vitro tests
and full genome sequencing of T. whipplei,h a v es h o w n
that the usual long-term treatment based on trimetho-
prim-sulfamethoxazole is a sulfonamide monotherapy
and that an alternative may be doxycycline and hydroxy-
chloroquine, an alkalinising agent [1,60,61]. However, it
is noteworthy to remember that trimethoprim-sulfa-
methoxazole has replaced cyclines, which had the repu-
tation of not crossing the blood-brain barrier in
adequate amounts, an issue that has not yet been con-
firmed for doxycycline [10]. That is why we first used a
combination of doxycycline, hydroxychloroquine and tri-
methoprim-sulfamethoxazole to manage T. whipplei
encephalitis. However, recent evidence suggests that sul-
fadiazine is preferable; its efficacy is comparable to that
of the sulfomethoxazole, but a higher dose of sulfadia-
zine can be used to improve its ability to cross the
blood-brain barrier [10]. Antibiotics had a quick effect.
However, 3 of our 5 patients presented with clinical
relapse despite at least 18 months of therapy. When the
treatment was reintroduced, a quick effect was again
observed. As for classic Whipple’s disease, the optimal
treatment for T. whipplei encephalitis has not yet been
determined [10]. Overall, the data emphasise the need
for long-term treatment and lifelong follow-up.
Conclusion
We describe a clinical entity that presents with unex-
plained progressive dementia, generally associated with
ataxia or recent obesity, and responds dramatically to
antibiotics. We suspect that many more cases may be
observed, as 3 of the recorded patients were hospitalised
in Marseille, where the study was performed.
Additional material
Additional File 1: Figure S1. Magnetic resonance spectroscopy results*
of patient 1.
Additional file 2: Table S1. Summary of 20 patients with T. whipplei
chronic encephalitis
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